-+ 0.00%
-+ 0.00%
-+ 0.00%

ADMA Biologics Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $559.495M Est

Benzinga·08/05/2026 20:24:28
Listen to the news
ADMA Biologics (NASDAQ:ADMA) affirms FY2026 sales outlook from $530.000 million-$560.000 million to $530.000 million-$560.000 million vs $559.495 million estimate.